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Abstract: Tigecycline, a glycylcycline related to the tetracycline class of antibiotics, represents 
a new option for the treatment of complicated intra-abdominal and complicated skin and skin 
structure infections. It displays favorable activity in vitro against the most common causative 
Gram-positive, Gram-negative and anaerobic pathogens. In addition, tigecycline demonstrates 
activity against drug-resistant pathogens such as methicillin-resistant Staphylococcus aureus, 
vancomycin-resistant enterococci, and organisms (such as Escherichia coli and Klebsiella 
pneumoniae) producing extended-spectrum beta-lactamases. Tigecycline lacks activity in vitro 
against Pseudomonas and Proteus spp. In randomized clinical trials, tigecycline administered 
intravenously twice daily has demonstrated efﬁ  cacy similar to comparators for a variety of 
complicated skin and skin structure and complicated intra-abdominal infections. The potential 
for signiﬁ  cant drug interactions with tigecycline appears to be minimal. Dosing adjustment is 
needed for patients with severe hepatic impairment. The predominant side effect associated 
with its use to date has been gastrointestinal intolerance (nausea and vomiting).
Keywords: tigecycline, intra-abdominal infections, complicated skin and skin structure 
infections
Introduction
Tigecycline, formerly GAR-936 (Tygacil®; Wyeth Pharmaceuticals, Inc., Philadelphia, 
PA, USA), is a glycylcycline antimicrobial currently approved by the Food and 
Drug Administration (FDA) for the treatment of complicated intra-abdominal 
infections (cIAIs) and complicated skin and skin structure infections (cSSSIs) (Wyeth 
Pharmaceuticals 2007b). In addition to its broad spectrum in vitro activity against 
Gram-positives, Gram-negatives and anerobes, tigecycline demonstrates activity in 
vitro against MRSA, VRE, and ESBL-producing organisms (Wyeth Pharmaceuticals 
2007b). Therefore, it has potential applications in the management of polymicrobial 
infections or those due to resistant organisms.
Two of the most prevalent bacterial infections in clinical practice are cSSSIs 
and cIAIs. For example, surgical site infections are estimated to occur 500,000 
times per year among the 27 million surgical procedures performed (CDCP 1997). 
Studies evaluating the impact of surgical site infections have demonstrated that these 
infections are consistently associated with an increase in healthcare costs, prolonged 
hospitalizations, and an increase in morbidity and mortality (Vegas et al 1993; Kirkland 
et al 1999). Speciﬁ  cally, one study, evaluating cSSSI following hip replacement 
surgeries, found a median increased length of stay of 32.5 days directly related to the 
cSSSI; additionally, the morbidity rate associated with the cSSSI was 14.3% (Monge 
et al 2006). Similarly, the incidence of cIAIs is also difﬁ  cult to determine because of 
its inclusion of a broad range of diagnoses. Among these, complicated appendicitis Therapeutics and Clinical Risk Management 2007:3(6) 1060
Townsend et al
may occur in up to 30% of appendicitis cases (Cueto et al 
2006). Additionally, cIaIs account for considerable hospital 
cost (Solomkin, Mazuski et al 2003). Inappropriate treatment 
has been associated with both treatment failures as well 
as increased mortality (Solomkin, Mazuski et al 2003). 
For example, Sturkenboom et al (2005) found a clinical 
failure rate of 35.7% and a mortality rate of 10.7% among 
patients receiving initial inappropriate therapy with 
intraabdominal infections.
Effective management of both cIAIs and cSSSIs require 
the timely institution of appropriate antimicrobital therapy 
and, in select cases, surgical interventions (Solomkin, 
Mazuski et al 2003; Stevens et al 2005). However, increases 
in antibiotic resistance seen in bacteria commonly causing 
such infections has made selection of appropriate empiric 
therapy challenging (Bochicchio et al 2006; Moet et al 2007). 
Data recently published from a worldwide multi-center 
longitudinal antimicrobial resistance tracking program, the 
SENTRY Antimicrobial Surveillance Program, reported 
rates of methicillin-resistant Staphylococcus aureus (MRSA) 
causing skin and skin structure infections ranging from 22.8% 
in Europe to 35.9% in North America (Moet et al 2007). 
Isolation of vancomycin-resistant enterococci (VRE) ranged 
from 3.6% in Europe to 12.2% in North America. Furthermore, 
Gram-negative organisms have also demonstrated diminished 
susceptibility. For example, reported rates of multidrug-
resistant Pseudomonas aeruginosa and extended-spectrum 
beta-lactamase (ESBL) producing Klebsiella spp. were 3.2% 
and 11.3% in North America, and 24.7% and 48.0% in Latin 
America, respectively. ESBL-producing Escherichia coli 
rates ranged from 6.6% in North America to 15.1% in Latin 
America (Moet et al 2007).
Rates of resistant organisms isolated in patients with 
cIAIs are also increasing. In vitro susceptibilities for over 
7,000 E. coli isolates from patients with intra-abdominal 
infections varied according to geographic region (Bochicchio 
et al 2006). The rate of ESBL-producing E. coli worldwide 
was 8.9% from 2002–2004, with the highest rates in the 
Asia/Paciﬁ  c region (16.6%) (Bochicchio et al 2006).
The purpose of this article is to review the in vitro activity, 
pharmacokinetics, pharmacodynamics and clinical efﬁ  cacy 
and safety of tigecycline for the treatment of cIAIs and cSSSIs. 
Tigecycline’s role in therapy will also be discussed.
Overview of tigecycline
Pharmacology
Tigecycline (C29H39N5O8) is the first of a new class of 
antimicrobials called glycylcyclines, which are related 
to the tetracycline class (Wyeth Pharmaceuticals 2007b). 
Although structurally similar to minocycline, it differs 
primarily by the presence of a side chain addition at position 9 
(Figure 1). Tigecycline possesses a similar mechanism of action 
to tetracyclines in that it binds to the bacterial 30S ribosomal 
subunit, thereby inhibiting bacterial protein synthesis (Bergeron 
et al 1996). However, the binding afﬁ  nity for tigecycline to this 
ribosomal site is approximately 5 times that of tetracyclines 
(Bergeron et al 1996). Tigecycline also demonstrates 70S 
ribosomal subunit binding, with up to 100-fold greater afﬁ  nity 
as compared with tetracycline (Olson et al 2006).
Resistance to the tetracycline class most frequently 
involves protection of the ribosome and/or efﬂ  ux pumps 
(Chopra et al 1992; Speer et al 1992; Bergeron et al 1996) 
Binding to the 30S ribosomal subunit is thought to prevent 
ribosomal protection (Rasmussen et al 1994; Tally et al 
1995; Projan 2000; Chopra et al 2001; Zhanel et al 2004). 
Efﬂ  ux pumps are responsible for expelling drug from the 
intracellular to extracellular space, thus preventing action 
of the drug and therefore causing resistance (Li et al 1995; 
Poole et al 1996; Kohler et al 1997; Aires et al 1999; Mine 
et al 1999; Westbrock-Wadman et al 1999; Dean et al 2003). 
In contrast to tetracyclines, tigecycline is not usually affected 
by efﬂ  ux pumps. However, tigecycline is susceptible to 
efﬂ  ux pumps of the “resistance nodulation division” (RND) 
which are common among P. aeruginosa (Projan 2000); 
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tigecycline is a know substrate for the pumps, described as 
MexAB-OprM, MexCD-OprJ, MexEF-OprN and MexXY-
OprM (Dean et al 2003). While Acinetobacter baumannii is 
generally sensitive to tigecycline, it can possess 2 of these 
RND pumps. Therefore, although further study is needed, 
emerging resistance to tigecycline while on therapy may be 
a concern for this organism (Rice 2006). Tigecycline appears 
to be unaffected by other mechanisms of resistance, including 
enzyme target changes and target site modifications. 
Production of beta-lactamases (including ESBLs) also do 
not inﬂ  uence tigecycline’s antimicrobial activity (Wyeth 
Pharmaceuticals 2007b).
Microbiology
The Clinical and Laboratory Standards Institute (CLSI) has 
set the tigecycline in vitro minimum inhibitory concentration 
(MIC) susceptibility breakpoints for Streptococcus spp. 
(excluding S. pneumoniae) and Enterococcus faecalis 
(vancomycin-susceptible organisms) at  0.25 µg/mL. MIC 
breakpoints to be considered susceptible to tigecycline for 
S. aureus (including both MSSA and MRSA) are  0.5 µg/mL, 
while Enterobacteriaceae and anaerobes are set at  2 µg/mL 
and  4 µg/mL, respectively (CLSI 2003a, 2003b, 2004, 2005; 
Wyeth Pharmaceuticals 2007b). The European Committee on 
Antimicrobial Susceptibility Testing (EUCAST) susceptibility 
breakpoint for Enterobacteriaceae however, is  1 µg/mL, 
and breakpoints have not been established for anaerobes 
(EUCAST Steering Committee 2006).
Tigecycline displays excellent in vitro activity against 
most Gram-positive organisms (Sader et al 2005). A recent 
study evaluating 26,474 bloodstream infection isolates 
from 6 different continents found 99.4% (n = 8765) of 
S. aureus isolates susceptible with an MIC90 = 0.5 µg/mL
(range of  0.016–1 µg/mL) (Sader et al 2005). In this same 
study, 92.7% (n = 3258) of Enterococcus spp. were consid-
ered sensitive to tigecycline, with an MIC90 of 0.25 µg/mL 
(range of  0.016–2 µg/mL). Over 97 % (n = 605) of 
S. pneumoniae and viridans group streptococci (n = 378) were 
also considered susceptible, with MIC90 of  0.12 µg/mL 
(range  0.12–1 µg/mL) and  0.12 µg/mL (range  0.12–
0.5 µg/mL), respectively (Sader et al 2005).
In general, tigecycline demonstrated activity against 
Gram-positive bacteria resistant to other classes of antibiotics. 
Susceptibility of S. aureus to tigecycline appears to be 
independent of oxacillin susceptibility (Sader et al 2005). 
In addition, a vancomycin-resistant S. aureus strain 
(VRSA) isolated at Hershey Medical Center demonstrated 
an MIC of 0.125 µg/mL to tigecycline (Bogdanovich et al 
2005). Tigecycline also has potent in vitro activity against 
quinolone-resistant S. pneumoniae, with a reported MIC of 
0.12 µg/mL (Garrison et al 2007). For vancomycin-resistant 
E. faecium (n = 77) and vancomycin-resistant E. faecalis 
(n = 11), the MIC90 were 0.06 µg/mL and 0.12 µg/mL, 
respectively with 100% susceptibility in both species 
(Hoban et al 2005).
Tigecycline has shown potent in vitro activity against 
most Gram-negative organisms, with the exception of 
Proteus (n = 320) and Pseudomonas spp. (n = 1,338) with 
MIC90 (and ranges) of 4 µg/mL (0.25–16 µg/mL) and 
 32 µg/mL (0.008– 32 µg/mL), respectively (Sader et al 
2005). E. coli (n = 3217) and Klebsiella spp. (n = 1,503) are 
also susceptible to tigecycline. The MIC90 (and ranges) of 
0.25 g/mL (0.03–4 µg/mL) and 1 µg/mL (0.06–8 µg/mL) 
have been reported for these organisms, respectively (Sader 
et al 2005). Tigecycline also demonstrates activity against 
ESBL-producing strains of these pathogens. MIC90 (range) 
values for 142 ESBL-producing E. coli isolates and 278 
ESBL-producing K. pneumoniae isolates were 1 µg/mL 
(0.25–2 µg/mL) and 2 µg/mL (0.25–8 µg/mL), respectively 
(Bouchillon et al 2005b). MICs ranging 0.03–8 µg/mL and 
an MIC90 of 1 µg/mL was reported in the largest published 
study of Acinetobacter spp. isolates (n = 851) to date (Waites 
et al 2006). While several other in vitro studies have reported 
a high percentage of Acinetobacter spp. susceptible MICs 
according to CLSI criteria, many of these organisms would be 
considered resistant if utilizing EUCAST criteria (Bouchillon 
et al 2005a, 2005b; Sader et al 2005; Waites et al 2006). 
Tigecycline also remains active against carbapenem-resistant 
A. baumannii and pan-resistant A. baumannii according 
to 2 recent case reports, although tigecycline-resistant 
A. baumanii has emerged clinically (Bogaerts et al 2006; 
Taccone et al 2006; Peleg et al 2007).
Anaerobic activity of tigecycline has been studied in 
several clinical trials in which the results are summarized 
in a study by Bradford et al (Bradford et al 2005). Results 
from these studies demonstrate tigecycline’s potent anaerobic 
activity against Clostidium perfringens, Propionibacterium 
acnes, and Bacteroides fragilis. MICs for these organisms 
were below the CLSI susceptibility breakpoint of  4 µg/mL 
(Bradford et al 2005). Table 1 describes further the in vitro 
susceptibilities of tigecycline.
Pharmacokinetics
Tigecycline exhibits linear kinetics following intravenous 
(IV) administration (Muralidharan, Micalizzi et al 2005). Data 
from 103 healthy adult volunteers who received tigecycline Therapeutics and Clinical Risk Management 2007:3(6) 1062
Townsend et al
Table 1  In vitro susceptibilities of select aerobic and anaerobic organisms to tigecyclinea
Organism No.  of    MIC90b  MIC   %   References
 isolates    rangeb Susceptiblec 
Staphylococcus aureus 8765  0.5   0.016–1  99.4  (Sader et al 2005)
  MSSA  813  0.12  0.015–0.5  100  (Waites et al 2006)
  MRSA  879  0.25  0.03–0.5  100  (Waites et al 2006)
 VISA  19  0.5  0.06–1  NAd  (Petersen et al 2002)
Staphylococci, coagulase-  3570  0.5   0.016–2  97.5  (Sader et al 2005)
negative (CoNS)         
CoNS, methicillin   71  0.5  0.03–1  NAd  (Fritsche, Sader et al 2005)
susceptible        
CoNS, methicillin resistant  189  0.5   0.12–2 NAd  (Fritsche, Sader et al 2005)
S. pneumoniae 605   0.12   0.12–1 --e  (Sader et al 2005)
  S. pneumoniae, penicillin   279  0.5  NAd NAd  (Hoban et al 2005)
 susceptible         
  S. pneumoniae, penicillin-  54  0.25  NAd NAd  (Hoban et al 2005)
 resistant         
Streptococci, β-hemolytic 769   0.12   0.12–0.5  99.7  (Sader et al 2005)
Streptococci, viridans   378   0.12   0.12–0.05  98.1  (Sader et al 2005)
group        
Enterococci spp.  3258  0.25   0.016–2  92.7  (Sader et al 2005)
  Enterococcus spp.- 466  0.5   0.12–1 NAd  (Fritsche, Sader et al 2005)
 vancomycin  susceptible         
  Enterococcus spp.- 39  0.25  0.03–0.5  NAd  (Fritsche, Sader et al 2005)
 vancomycin  resistant         
Nocardia spp.  51  4   0.06–8 NAd  (Cercenado et al 2007)
Escherichia coli 3217  0.25  0.03–4   99.9  (Sader et al 2005)
 ESBL-producing  E.coli 115  0.38  0.047–0.75  NAd  (Sorlozano et al 2006)
Klebsiella pneumonia 1334  2  0.008–8  95  (Waites et al 2006)
  ESBL-producing   126  2  0.12–8  92.1  (Waites et al 2006)
K. pneumoniae        
Klebsiella oxytoca  248  1  0.06–4  98.8  (Waites et al 2006)
Enterobacter aerogenes  419  1  0.06–8  95.7  (Waites et al 2006)
Enterobacter cloacae 1089  2  0.008–8  93  (Waites et al 2006)
Haemophilus inﬂ  uenzae 336 0.25 NAd --e  (Hoban et al 2005)
  H. inﬂ  uenzae, β-lactamase   93  0.25  NAd --e  (Hoban et al 2005)
 positive         
Moraxella catarrhalis 54  0.5  NAd --e  (Gales et al 2005)
Serratia marscens  658  1  0.012–8  97  (Waites et al 2006)
Citrobacter spp.  252  0.5  NAd  86.9  (Fritsche, Strabala et al 2005)
Acinetobacter baumannii 851 1  0.03-8  --e  (Waites et al 2006)
Pseudomonas aeruginosa 1338   32   0.008– 32 --e  (Waites et al 2006)
Stenotrophomonas   203  2  0.12–8  --e  (Sader et al 2005)
maltophilia        
Burkholderia cepacia 21  16  0.25–32  --e  (Cheng et al 2005)
Campylobacter jejuni 108  4 0.12–16  --e  (Rodriguez-Avial et al 2006)
Campylobacter coli 8  16  0.5–16  --e  (Rodriguez-Avial et al 2006)
Proteus mirabilis  320  4  0.25–16  46.9  (Sader et al 2005)
Bacteroides fragilis  2721  8  0.06–32  94.9  (Snydman et al 2007)
Bacteroides fragilis group  5225  8  0.06–64  95.7  (Snydman et al 2007)
  B. distasonis  274  8  0.25–32  97.9  (Snydman et al 2007)
  B. ovatus  545  8  0.125–16  96.7  (Snydman et al 2007)
  B. thetaiotaomicron  978  8  0.25–32  96.4  (Snydman et al 2007)
  B. vulgatus  306  4  0.25–16  98.4  (Snydman et al 2007)
C. perfringens 51  1.0   0.06–2 NAd  (Bradford et al 2005)
Clostridium difﬁ  cile 12  0.06  0.06  NAd  (Goldstein et al 2006)
Fusobacterium varium 13  0.25  0.06–0.25  NAd  (Goldstein et al 2006)
Lactobacillus spp.  15  0.5  0.06–1  NAd  (Goldstein et al 2006)
aAdapted with permission from (Townsend ML et al 2006.  Tigecycline:  a new glycylcycline antimicrobial. Int J Clin Pract, 60:1662–72. Blackwell Publishing.) bMIC = minimum 
inhibitory concentration. cAccording to CLSI criteria. dNA= not available. eNo CLSI criteria available.Therapeutics and Clinical Risk Management 2007:3(6) 1063
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intravenously (100 mg followed by 50 mg every 12 hours over 
60 minutes) produced steady state maximum plasma concen-
trations (Cmax) and minimum plasma concentrations (Cmin) of 
0.63 µg/mL and 0.13 µg/mL, respectively. The area under the 
plasma concentration-time curve from 0 to 24 hours (AUC0–24) 
was 4.70 µg·h/mL (Muralidharan, Micalizzi, et al 2005; Wyeth 
Pharmaceuticals 2007b). Patients with cSSSIs (n = 81) partici-
pating in a phase II study demonstrated pharmacokinetic param-
eters similar to healthy adult volunteers, with a Cmax of 0.403 
µg/ml and AUC0–12 of 2.24 µg·h/mL (Postier et al 2004).
Tigecycline is highly protein bound (71%–89%) at 
plasma drug concentrations achieved in clinical trials 
(0.1–1.0 µg/mL) (Wyeth Pharmaceuticals 2007b). The 
volume of distribution of tigecycline reported from healthy 
volunteer studies is 7–10 L/kg (Muralidharan, Micalizzi et al 
2005). Based on animal and human studies, tigecycline can 
distribute into various bodily ﬂ  uids and tissues, such as the 
lungs, skin, peritoneal ﬂ  uid, gall bladder, colon, heart, liver, 
meninges and bone (Tombs 1999; Rodvold et al 2005; Conte 
et al 2005; Gotfried et al 2005; Sun et al 2005; Rodvold et al 
2006; Scheetz et al 2006; Wyeth Pharmaceuticals 2007b). In 
adults undergoing medical or surgical procedures (n = 104), 
serum, tissue, and body ﬂ  uid concentrations of tigecycline 
were evaluated following a single dose of 100 mg of 
tigecycline administered over 30 minutes (Rodvold et al 
2006). The mean ratio of tigecycline in the tissue to serum 
(expressed as AUC0–24) was 537 in the bile, 23 for the gall 
bladder, 2.6 for the colon, and 2.0 for the lung (Rodvold 
et al 2006). The highest concentration of tigecycline was 
found in the bile, which is consistent with the drug’s known 
route of elimination. Additionally, lower tissue to serum 
concentrations were achieved in the bone, synovial ﬂ  uid, and 
cerebrospinal ﬂ  uid (CSF). The mean ratio of tigecycline in the 
tissue to serum (expressed as AUC0–24) was 0.41 for the bone, 
0.31 for the synovial ﬂ  uid, and 0.11 for the CSF. The highest 
CSF to serum ratios occurred approximately 24 hours after 
infusion. Of note, bone penetration of tigecycline in animal 
models was higher than what was achieved in this human 
study (Tombs 1999; Rodvold et al 2006). The inconsistency 
of bone penetration in this study versus previous animal 
studies may have been due to poor extraction techniques, 
tight binding of the drug to bone, or the single dose design 
of the study. Additionally, peritoneal ﬂ  uid penetration of 
tigecycline has been reported in a critically ill patient. The 
extrapolated penetration into the peritoneal ﬂ  uid was about 
50% (Scheetz et al 2006). Tigecycline has also been shown 
to have a 74% (mean) penetration into cantharidin-induced 
blisters in healthy volunteers (n = 10) (Sun et al 2005).
Tigecycline is not extensively metabolized. The main 
metabolic pathway of tigecycline is glucuronidation. Non-
active metabolites that were recovered in the urine and feces 
include a glucuronide, its epimer (M1 and M2), and N-acetyl-
9-aminominocycline (M6) (Hoffmann et al 2004; Rello 2005; 
Wyeth Pharmaceuticals 2007b). The pharmacokinetic model 
of tigecycline follows a 2-compartment model with ﬁ  rst-
order elimination based on pooled data from Phase II and III 
studies involving patients with cSSSIs and cIAIs (Van Wart 
et al 2006). The primary route of elimination of tigecycline 
is through feces and the biliary tract (59%) as unchanged 
drug and metabolites. Secondary routes of elimination 
include glucuronidation and renal excretion (33%). Renal 
excretion only accounts for about 10%–15% of the systemic 
clearance of tigecycline (Hoffmann et al 2004; Muralidharan, 
Micalizzi et al 2005). The terminal half-life of tigecycline 
is 37–67 hours and the total systemic clearance is 0.2–0.3 
L/h/kg (Muralidharan, Micalizzi et al 2005).
Pharmacodynamics
Tigecycline demonstrates time-dependent bacteriostatic 
activity in vitro (van Ogtrop et al 2000; Reese et al 2005). Its 
post-antibiotic effect against Gram-negative organisms ranges 
from 2 to 5 hours, and 8.9 hours for S. pneumoniae (van Ogtrop 
et al 2000; Reese et al 2005). Recent animal and clinical data 
suggests the area-under-the concentration-time curve (AUC) 
to MIC ratio (AUC/MIC) may be a reliable predictor for 
efﬁ  cacy with tigecycline (Meagher et al 2005; Garrison et al 
2007; Meagher et al 2007). The AUC/MIC ratios described 
in the literature for in vitro activity range from 79–158 
when evaluating quinolone-resistant S. pneumoniae, MRSA 
and VRE (Garrison et al 2007). In a study by Meagher and 
colleagues (Meagher et al 2007), cSSSI patients with S.aureus 
and streptococci as the primary organisms were evaluated to 
determine the pharmacodynamic properties of tigecycline. 
Based on the results of this study, the AUC/MIC ratio of 17.9 
or higher was a signiﬁ  cant predictor of both microbiological 
and clinical response in cSSSI patients (Meagher et al 
2007). Although the AUC/MIC ratios range in the literature 
depending on the organism and infection, no consensus to date 
has been reached to determine the ideal AUC/MIC ratio for 
particular disease states.
Special populations
Tigecycline’s pharmacokinetic proﬁ  le appears to be inde-
pendent of age, ethnic backgrounds (African-American, 
Hispanic, Asian, and Caucasian), and gender. (Meagher 
et al 2005; Muralidharan, Fruncillo et al 2005). Patients with Therapeutics and Clinical Risk Management 2007:3(6) 1064
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renal impairment (creatinine clearance of  30 mL/min or 
hemodialysis-dependent) had a non-signiﬁ  cant increase in 
Cmax and AUC in comparison to healthy volunteers (Troy 
et al 2003). Additionally, tigecycline was not found to be 
signiﬁ  cantly removed via hemodialysis. Therefore, no dosing 
adjustments are necessary in patients with renal dysfunction 
or who are hemodialysis dependent (Troy et al 2003; Wyeth 
Pharmaceuticals 2007b). In contrast to patients with renal dys-
function, patients with severe hepatic impairment (ie, Child-
Pugh Class C) had a 43% increase in tigecycline’s half-life and 
a 55% reduction in drug clearance (Saunders et al 2005). Thus, 
it is recommended in these patients that the maintenance dose 
of tigecycline be reduced to 25 mg every 12 hours in patients 
with severe hepatic insufﬁ  ciency (Wyeth Pharmaceuticals 
2007b). No adjustments are needed for patients with mild 
to moderate hepatic impairment (Child-Pugh Class A or B) 
(Wyeth Pharmaceuticals 2007b). Pharmacokinetic studies 
are currently lacking in obese/low-body-weight individuals, 
the pediatric population, and patients who are lactating 
or pregnant.
Drug interactions
To date, no signiﬁ  cant drug-drug interactions have been 
reported with tigecycline. Tigecycline is not metabolized 
by the cytochrome P450 system and as a result, it does not 
alter the metabolism of drugs that go through this system 
nor do these drugs affect the concentration of tigecycline 
(Wyeth Pharmaceuticals 2007b). Studies evaluating the 
concurrent administration of tigecycline with either digoxin 
or warfarin in healthy adults have not demonstrated a 
signiﬁ  cant drug-drug interaction between tigecycline and 
either of these drugs (Zimmerman et al 2004; Raible et al 
2005; Wyeth Pharmaceuticals 2007b; Zimmerman et al 
2007). However, the manufacturer of tigecycline does 
recommend that the international normalized ratio (INR) 
as well as signs and symptoms of bleeding be routinely 
assessed when tigecycline is administered with warfarin 
(Wyeth Pharmaceuticals 2007b).
Safety and tolerability
Overall, tigecycline was well-tolerated in phase III clinical 
studies with only 5% of patients discontinuing therapy due 
to adverse events in comparison to 4.7% in the comparator 
arms (vancomycin-aztreonam 5.3% and imipenem-cilastatin 
4.4%) (Babinchak et al 2005; Ellis-Grosse, Babinchak et al 
2005; Wyeth Pharmaceuticals 2007b).
The most common adverse events associated with the 
administration of tigecycline in phase II and III studies was 
mild to moderate nausea and vomiting. This occurred most 
often during the ﬁ  rst 2 days of drug therapy, and was the most 
common reason for discontinuing drug therapy (Postier et al 
2004; Oliva et al 2005; Babinchak et al 2005; Breedt et al 
2005; Fomin et al 2005; Muralidharan, Fruncillo et al 2005; 
Muralidharan, Micalizzi et al 2005; Sacchidanand et al 2005; 
Wyeth Pharmaceuticals 2007b). The incidence of nausea was 
34.5% (versus 8.2% in vancomycin-aztreonam; p   0.001) 
in the cSSSIs studies and 24.4% (versus 19% in imipenem-
cilastatin; p = 0.01) in the cIAIs studies. The incidence of 
vomiting was 19.6% (versus 3.6% in vancomycin-aztreonam; 
p   0.001) and 19.2% (versus 14.3% in imipenem-cilastatin; 
p = 0.008) in cSSSIs and cIAIs studies, respectively (Oliva 
et al 2005; Babinchak et al 2005; Fomin et al 2005; Breedt 
et al 2005; Ellis-Grosse, Babinchak et al 2005). The exact 
mechanism of tigecycline-induced nausea and vomiting 
remains unknown, but it is not related to the release of sero-
tonin in the gastrointestinal tract (Muralidharan, Micalizzi et al 
2005). Nausea and vomiting has occurred more frequently at 
higher doses and in patients  50 years of age, female, and 
non-European descent (Muralidharan, Fruncillo et al 2005; 
Wyeth Pharmaceuticals 2007b). While coadministration of 
food may potentially improve the tolerability of tigecycline, 
altering the rate of infusion has not been successful in deceas-
ing the incidence of nausea and vomiting (Muralidharan, 
Micalizzi et al 2005). Likewise, administration of antiemetics 
(such as prochlorperazine, ondansetron, or metoclopramide) 
does not signiﬁ  cantly alter the incidence of nausea and vomit-
ing (Muralidharan, Micalizzi et al 2005; Wyeth Pharmaceu-
ticals 2007b). During phase III clinical studies, diarrhea was 
reported in 12.7% of patients receiving tigecycline (Wyeth 
Pharmaceuticals 2007b). However, there were no published 
cases of Clostridium difﬁ  cile associated diarrhea in these clini-
cal studies (Babinchak et al 2005; Ellis-Grosse, Babinchak 
et al 2005; Wyeth Pharmaceuticals 2007b).
Tigecycline’s ability to induce C. difﬁ  cile infections has 
also been evaluated (Baines et al 2006). In a human gut model 
involving 2 epidemic strains of C. difﬁ  cile, the gut ﬂ  ora was 
signiﬁ  cantly decreased although the C. difﬁ  cile spores did 
not “proliferate”; in addition, cytotoxin was not produced 
(Baines et al 2006). This seems to correlate clinically, as only 
limited cases of C. difﬁ  cile infections have been reported with 
tigecycline to date (Wyeth Pharmaceuticals 2007a). However, 
as with all antimicrobials, tigecycline can theoretically 
predispose a patient to a C. difﬁ  cile infection.
Due to the structural similarities between tetracyclines 
and tigecycline, cross-reactivity may occur between these two 
classes of drugs, and caution should be used in patients with Therapeutics and Clinical Risk Management 2007:3(6) 1065
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known hypersensitivity reactions to tetracyclines (Zhanel 
et al 2004; Wyeth Pharmaceuticals 2007b). Furthermore, 
similar side effects may exist between tetracyclines and 
tigecycline such as photosensitivity reactions, pancreatitis, 
and tooth discoloration in children under 8 years old (Zhanel 
et al 2004; Wyeth Pharmaceuticals 2007b). Long-term safety 
has not been published with the use of tigecycline to date.
Clinical efﬁ  cacy
Complicated intra-abdominal infections
As with any type of infection, the objectives for the treatment 
of cIAI are to minimize the time to clinical improvement, pre-
vent recurrence, and eradicate the causative microorganisms. 
As with most infections, healthcare-associated infectious 
diseases generally require broader antibacterial coverage for 
such resistant organisms as P. aerunginosa, Enterobacter 
spp. and MRSA as compared with community-associated 
infections (Solomkin, Mazuski et al 2003).
Guidelines published by the Infectious Diseases Society 
of America for the treatment of cIAIs describe the use of a 
single-agent, broad-spectrum antimicrobial agent or the use 
of a combination of antibiotics with activity against common 
enteric ﬂ  ora (Solomkin, Mazuski et al 2003). They summarize 
data from numerous trials. For example, monotherapy for 
the treatment of cIAIs studied in randomized, prospective 
clinical trials include the β-lactam/β-lactamase inhibitors 
such as ampicillin/sulbactam, piperacillin/tazobactam, and 
ticarcillin/clavulanic acid (Eklund et al 1993; Walker et al 
1993; Dougherty et al 1995; Jaccard et al 1998; Allo et al 
1999; Ohlin et al 1999; Cohn et al 2000). The carbapenems 
(ertapenem, imipenem/cilastatin and meropenem) as well as 
certain cephalosporins (ceftotetan and cefoxitin) have also 
been studied (Poenaru et al 1990; Brismar et al 1992; Eklund 
et al 1993; Brismar et al 1995; Condon et al 1995; Geroulanos 
1995; Huizinga et al 1995; Angeras et al 1996; Berne et al 
1996; Christou et al 1996; Colardyn et al 1996; Solomkin 
et al 1996; Barie et al 1997; Basoli et al 1997; Donahue 
et al 1998; Allo et al 1999; Solomkin et al 2001; Solomkin, 
Mazuski et al 2003; Solomkin, Yellin et al 2003). As for com-
bination regimens, aminoglycosides, quinolones or certain 
cephalosporin agents in addition to anti-anaerobic medications 
(clindamycin or metronidazole) also have data to support their 
use (Solomkin, Mazuski et al 2003).
Tigecycline has been studied speciﬁ  cally in adult patients 
with cIAIs in 2 phase III, noninferiority, multicenter, 
randomized, double-blind trials (Oliva et al 2005; Fomin 
et al 2005) and are presented together in a pooled analysis 
(Babinchak et al 2005). Patients 18 years old and older who 
also required surgical intervention for treatment of cIAIs were 
included. The cIAIs were deﬁ  ned as perforated intestines, 
intra-abdominal abscesses, appendicitis, diverticulitis, or 
cholecysitis with perforation and/or abscess with fecal 
contamination, or perforated gastric/duodenal ulcers, and 
complicated peritonitis (Babinchak et al 2005). Patients were 
stratiﬁ  ed by randomization according to their APACHE II 
scores and received either intravenous tigecycline 100 mg 
followed by 50 mg every 12 hours or intravenous imipenem-
cilastatin 500 mg every 6 hours (adjusted based on the 
patient’s weight and renal function). Patients were generally 
treated for 5–14 days.
The primary endpoint for these studies was “the clinical 
response at the test-of-cure visit (12–42 days after therapy) 
in the co-primary end point microbiologically evaluable 
[ME] and microbiological modiﬁ  ed intent-to-treat [mm-ITT] 
populations” (Babinchak et al 2005).
A total of 1658 patients were randomized in these 
2 trials; the mm-ITT population included 1262 patients, 
and the ME population was composed of 1025 patients. The 
mean of subject age was 47 years, and the most commonly 
reported intra-abdominal infection was complicated appen-
dicitis (50.6%, tigecycline and 48.7%, imipenem-cilastatin) 
followed by complicated cholecystitis (12.8%, tigecycline 
and 15.1%, imipenem-cilastatin). The average APACHE 
II score was 6.3 (tigecycline group) and 6 (imipenem-
cilastatin) with only 35 patients having an APACHE II score 
 15. The mean duration of therapy with either agent was 
approximately 8 days (Babinchak et al 2005). Clinical cures 
were reported in 80.2% (506/631) and 81.5% (514/631) of 
tigecycline and imipenem m-mITT groups, respectively 
(% difference (95%CI): −1.3% (–5.8% to 3.2%)). The ME 
population had similar response rates, with 86.1% (441/512) 
and 86.2% (442/513) clinical cure rate in the tigecycline and 
imipenem-cilastatin groups, respectively (Babinchak et al 
2005). Although many organisms were identiﬁ  ed, the most 
commonly isolated organisms included E. coli (n = 665), 
S. anginosus (n = 198), K. pneumonia (n = 112) and B. fragilis 
(n = 160) (Babinchak et al 2005). The most commonly 
reported adverse events reported in these studies included 
gastrointestinal complaints with a statistically higher rate in 
the tigecycline group compared with those receiving imi-
penem-cilastatin. There were a total of 44.4% and 39.4% 
of reported adverse events with the digestive system in the 
tigecycline and imipenem-cilastatin patients, respectively 
(p = 0.04) (Babinchak et al 2005).
Based on the results of this analysis, tigecycline appears to 
be as safe and effective as imipenem in cIAIs. One limitation Therapeutics and Clinical Risk Management 2007:3(6) 1066
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in this trial was the relatively few resistant organisms isolated. 
Thus, these studies may not apply to the patient population 
in which resistance is a concern. Additional clinical trials 
examining tigecycline’s use in cIAIs including resistant 
organisms will further the utility of tigecycline in this type 
of infection.
Complicated skin and skin structure 
infections
Complicated skin and skin structure infections (cSSSIs) either 
involve deep soft tissues or require surgical debridement 
or interventions. These infections often require parenteral 
antimicrobial treatment and frequently occur in patients with 
other comorbid disease states (such as diabetes or peripheral 
vascular disease) in which their response to antimicrobial 
treatment can be suboptimal. Examples of cSSSIs include 
major abscesses, burns, surgical site infections, diabetic 
foot, and infected ulcers (CDER 1998; Nichols 1999, 2001; 
Dinubile et al 2004; Lee et al 2005).
Numerous pathogens have been associated with cSSSIs 
and are often dependent upon the patient and clinical sce-
nario. In general though, S. aureus and Streptococcus spp. 
tend to be the predominant pathogens with Gram-negatives, 
anaerobes, and resistant pathogens such as MRSA becoming 
more of a factor in immunocompromised patients, injection 
drug users, and nosocomially-acquired infections (Rennie 
et al 2003; Dinubile et al 2004). Additionally, some infec-
tions (such as lower extremity infections in diabetic patients) 
tend to be more polymicrobial in nature (Doern et al 1999; 
Rennie et al 2003; Dinubile et al 2004).
Besides surgical debridement, there are multiple antimi-
crobial options that are available for the treatment of cSSSIs. 
Empiric antimicrobial therapy should include coverage for 
Gram-positive cocci such as staphlococci and streptococci. 
Additional coverage for Gram-negative organisms, anaer-
obes (such as B. fragilis group), or resistant pathogens is 
dependent upon patient risk factors for such organisms 
(Nichols 1999; Dinubile et al 2004; Stevens et al 2005; Lee 
et al 2005). Local resistance patterns should also play an 
important role in deciding appropriate empiric treatment. 
According to the skin and soft tissue infections guidelines 
set forth by the Infectious Diseases Society of America (Fass 
et al 1985; Tan et al 1993; Talan et al 2000; Grayson et al 
2002; Graham, Lucasti et al 2002; Graham, Talan et al 2002; 
Stevens et al 2005; Fabian et al 2005; Giordano et al 2005), 
treatment options include broad-spectrum antibiotics such 
as carbapenems (eg, imipenem/cilastin, meropenem, ertap-
enem), beta-lactam/beta-lactamase inhibitor combinations 
(eg, piperacillin-tazobactam, ticarcillin-clavulanate,
ampicillin-sulbactam), cephalosporins (eg, cefazolin, cefoxi-
tin), and ﬂ  uoroquinolones (eg, levoﬂ  oxacin, moxiﬂ  oxacin) 
used alone or in combination with clindamycin or metroni-
dazole for anerobic coverage. The addition of vancomycin or 
other newer antimicrobial agents (eg, daptomycin, linezolid, 
quinupristin/dalfopristin, tigecycline) with activity against 
resistant organisms such as MRSA, VRE, and ESBL-
producing gram negative organisms is dependent upon the 
clinical circumstances of the patient (Nichols et al 1999; 
Stevens et al 2000; Stevens et al 2005; Lipsky et al 2005).
Tigecycline has been evaluated for the treatment of cSSSIs 
in two randomized, multi-centered, double-blind phase 3 
studies (Breedt et al 2005; Ellis-Grosse, Babinchak et al 2005; 
Sacchidanand et al 2005). In both studies, hospitalized adult 
patients with cSSSIs (deﬁ  ned as deep soft tissue infections, 
soft tissue infections requiring surgical debridement, or soft 
tissue infections in patients with underlying disease such as 
diabetes or peripheral vascular disease) were randomized (1:1) 
to receive either tigecycline (100 mg loading dose followed 
by 50 mg every 12 hours over 60 minutes) or vancomycin 
(1 g every 12 hours over 60 minutes with adjustments based 
on renal function) plus aztreonam (2 g every 12 hours over 
60 minutes) intravenously for up to 14 days. At the discretion 
of the investigators, aztreonam therapy could be discontinued 
after 48 hours of treatment. The clinical response at the test-
of-cure-visit (12–92 days after the last dose) in the clinically 
evaluable (CE) and the clinical modiﬁ  ed intention-to-treat 
(c-mITT) was the primary endpoint of these studies (Ellis-
Grosse, Babinchak et al 2005).
Pooled analysis of the data (N = 1129) demonstrated that 
baseline demographics between each group was similar in 
terms of type of infection and incidence of other comorbid 
disease states (Ellis-Grosse, Babinchak et al 2005). Cauca-
sian (68.2%) men (62.1%) with a mean age of 48 made up 
the majority of the patients enrolled in the studies. Patients 
were on antibiotic treatment for a mean of 8 days in each 
group. The most common type of cSSSIs was cellulitis 
(59%). In the c-mITT analysis (comprised of patients who 
received at least 1 dose of the study drug and had clinical 
evidence of a cSSSI; ) (N = 1057), 79.7% in the tigecycline 
arm (429/538) versus 81.9% in the vancomycin-aztreonam 
arm (425/519) [95% CI for the difference –2.1 (–7.1% to 
2.8%)] had a clinical cure, deﬁ  ned as resolution of the signs 
and symptoms of cSSSI and completion of antibiotic therapy. 
Clinical cure rates for the CE population (deﬁ  ned as c-mITT 
population without P. aeruginosa as sole isolate, no other 
concurrent antibiotic therapy, and assessed for failure or cure Therapeutics and Clinical Risk Management 2007:3(6) 1067
Tigecycline review
at the TOC visit) (N = 833) were 86.5% for patients receiving 
tigecycline (365/422) versus 88.6% in the comparator arm 
(364/411) [95% CI for the difference, –2.1 (–6.8 to 2.7)]. The 
most common organism isolated was MSSA (N = 254). Cure 
rates for MSSA were 88.8% (N = 119/134) versus 90.8% 
(N = 109/120), respectively for tigecycline and vancomycin-
aztreonam arms. Sixty-ﬁ  ve patients had MRSA isolates, of 
which 32% (N = 21/65) were considered to be community-
acquired strains. Overall cure rates for MRSA were 78.1% 
(N = 25/32) in the tigecycline arm and 75.8% (N = 25/33) 
for the vancomycin-aztreonam arm (Ellis-Grosse, Babinchak 
et al 2005). ESBL-producing organisms treated with tige-
cycline had clinical cure rates of 77.8% (N = 9) for E. coli, 
85.7% (N = 7) for K. pneumoniae, and 100% (N = 3) for 
P. mirabilis (Ellis-Grosse, Bradford et al 2005). The authors 
concluded from these pooled analysis, that tigecycline was 
noninferior to the combination of vancomycin-aztreonam 
in the treatment of cSSSIs. The incident of adverse events 
was similar between the groups (67.7% tigecycline versus 
61.1% vancomycin-aztreonam) with the most common 
adverse events being related to gastrointestinal complaints 
(46% tigecycline versus 21% vancomycin-aztreonam; p   
0.001) (Ellis-Grosse, Babinchak et al 2005).
Conclusions
Tigecycline represents a new treatment option for both 
cSSSIs and cIAIs due, in part, to its favorable in vitro 
activity against a wide variety of aerobic Gram-positive, 
Gram-negative and anaerobic organisms (including 
multidrug-resistant pathogens such as MRSA, VRE, 
and ESBL-producing strains of E. coli and Klebsiella). 
In contrast, tigecycline lacks activity in vitro against 
P. aeruginosa and P. mirabilis. Following twice daily 
intravenous administration, it is extensively distributed 
to various body tissues and ﬂ  uids. Dose modiﬁ  cation is 
required in patients with signiﬁ  cant hepatic impairment. 
Because of the metabolic proﬁ  le of tigecycline, the potential 
for drug interactions appears to be minimal.
Based on existing clinical efﬁ  cacy and safety data, tige-
cycline has been FDA-approved for use as monotherapy 
for the treatment of cSSSIs and cIAIs. Published clinical 
efﬁ  cacy data in humans reports tigecycline as noninferior 
to comparators for such indications. Tigecycline might be 
particularly useful in suspected or documented polymicro-
bial infections, including those patients otherwise requiring 
combination therapies due to the presence of drug-resistant 
pathogens such as MRSA, VRE, or ESBL-producing strains 
of E. coli and K. pneumoniae. In contrast, its role as part of 
combination therapy with other antimicrobials is uncertain. 
Gastrointestinal side effects (mainly nausea) may be prob-
lematic in some patients.
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